Fingolimod — Membership Pricing

Other medications in Neurological

• Fosphenytoin
• Fremanezumab
• Galantamine
• Galcanezumab
• Glatiramer
• Interferon Beta-1a
• Interferon Beta-1b
• Lacosamide

About Fingolimod

Fingolimod is a critical medication used to manage relapsing forms of multiple sclerosis (MS), working to reduce disease activity and slow progression. While its therapeutic benefits are significant, the cost can be a major concern for many patients. TheDrugClub is committed to making essential treatments like fingolimod more accessible and affordable, helping you find relief without financial strain.

Multiple Sclerosis (MS) is a chronic, often debilitating autoimmune disease that affects the brain and spinal cord, leading to a range of symptoms from fatigue and numbness to mobility issues and vision problems. For individuals living with relapsing forms of MS, medications like fingolimod play a crucial role in managing the condition, reducing the frequency of relapses, and slowing the accumulation of disability.

What Fingolimod Treats and How It Works

Fingolimod is primarily prescribed for adults and children aged 10 years and older with relapsing forms of MS. It belongs to a class of drugs called sphingosine 1-phosphate (S1P) receptor modulators. Its mechanism of action is quite unique: it works by preventing certain white blood cells, specifically lymphocytes, from leaving the lymph nodes. By trapping these immune cells, fingolimod reduces their number circulating in the blood and, crucially, their ability to enter the central nervous system (CNS). In MS, these lymphocytes contribute to the inflammatory attacks that damage myelin – the protective sheath around nerve fibers – leading to MS symptoms. By limiting their access to the CNS, fingolimod helps to reduce inflammation and protect nerve cells from further damage, thereby decreasing the frequency and severity of MS relapses.

Understanding the Cost of Fingolimod

As a specialized medication for a complex chronic condition, fingolimod typically comes with a high price tag. Without insurance

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Fingolimod is approved for (FDA label)

Fingolimod Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. Fingolimod Capsules are sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: August 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Fingolimod (FDA label)

Fingolimod Capsules are available as: 0.5 mg capsules are size “3” hard gelatin capsules having white opaque cap imprinted “0.5 mg" and white opaque body imprinted "MF" with black ink, filledwith white to off white colored fine powder. 0.5 mg hard capsules ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: bd981e18-1766-4a2d-9a9b-965ec960aa06. SPL document ID: cf02c267-5b60-4b85-be94-83840e630859. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Fingolimod (FDA label)

The following serious adverse reactions are described elsewhere in labeling: Bradyarrhythmia and Atrioventricular Blocks [ see Warnings and Precautions (5.1) ] Infections [ see Warnings and Precautions (5.2) ] Progressive Multifocal Leukoencephalopathy [ see Warnings and Precautions (5.3) ] Macular Edema [ see Warnings and Precautions (5.4) ] Liver Injury [ see Warnings and Precautions (5.5) ] Posterior Reversible Encephalopathy Syndrome [ see Warnings and Precautions (5.6) ] Respiratory Effects [ see Warnings and Precautions (5.7) ] Fetal Risk [ see Warnings and Precautions (5.8) ] Severe Increase in Disability After Stopping Fingolimod Capsules [ see Warnings and Precautions (5.9) ] Tumefactive Multiple Sclerosis [ see Warnings and Precautions (5.10) ] Increased Blood Pressure [ see Warnings and Precautions (5.11) ] Malignancies [ see Warnings and Precautions (5.12) ] Immune System Effects Following Fingolimod Capsules Discontinuation [ see Warnings and Precautions (5.13) ] Hypersensitivity Reactions [ see Warnings and Precautions (5.14)] Most common adverse reactions (incidence ≥ 10% and greater than placebo): Headache, liver transaminase elevation, diarrhea, cough, influenza, sinusitis, back pain, abdominal pain, and pain in extremity. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: bd981e18-1766-4a2d-9a9b-965ec960aa06. SPL document ID: cf02c267-5b60-4b85-be94-83840e630859. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Fingolimod (FDA label)

Fingolimod Capsules are contraindicated in patients who have: in the last 6 months experienced myocardial infarction, unstable angina, stroke,transient ischemic attack (TIA), decompensated heart failure requiring hospitalization or Class III/IV heart failure a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker [ see Warnings and Precautions (5.1) ] a baseline QTc interval ≥ 500 msec cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs had a hypersensitivity reaction to fingolimod or any of the excipients in Fingolimod Capsules.

Source: FDA prescribing information (DailyMed). Set ID: bd981e18-1766-4a2d-9a9b-965ec960aa06. SPL document ID: cf02c267-5b60-4b85-be94-83840e630859. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Fingolimod (FDA label)

Infections : Fingolimod Capsules may increase the risk. Obtain a complete blood count (CBC) before initiating treatment. Monitor for infection during treatment and for 2 months after discontinuation. Do not start in patients with active infections. ( 5.2 ) Progressive Multifocal Leukoencephalopathy (PML) : Withhold Fingolimod Capsules at the first sign or symptom suggestive of PML. ( 5.3 ) Macular Edema: Increases the risk of macular edema. Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment with fingolimod capsules. Conduct an evaluation of the fundus, including the macula, 3 to 4 months after treatment start, periodically while on therapy and any time there is a change in vision. Consider discontinuing fingolimod capsules if macular edema develops. Diabetes mellitus and uveitis increase the risk. ( 5.4 ) Liver Injury : Obtain liver enzyme results before initiation and periodically during treatment.

Source: FDA prescribing information (DailyMed). Set ID: bd981e18-1766-4a2d-9a9b-965ec960aa06. SPL document ID: cf02c267-5b60-4b85-be94-83840e630859. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Fingolimod (FDA label)

Systemic Ketoconazole : Monitor during concomitant use. ( 7.2 , 12.3 ) Vaccines : Avoid live attenuated vaccines during, and for 2 months after stopping fingolimod treatment. ( 5.2 , 7.3 ) 7.1 QT Prolonging Drugs Fingolimod Capsules has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of Fingolimod Capsules treatment results in decreased heart rate and may prolong the QT interval, patients on QT- prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility [ see Dosage and Administration (2.4) , Warnings and Precautions (5.1) ]. 7.2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole.

Source: FDA prescribing information (DailyMed). Set ID: bd981e18-1766-4a2d-9a9b-965ec960aa06. SPL document ID: cf02c267-5b60-4b85-be94-83840e630859. Label effective date: August 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.